Guardant Health, Inc. - Common Stock (GH)
Frequently Asked Questions About Guardant Health, Inc. - Common Stock (GH)
How does Guardant Health contribute to clinical trials?
Guardant Health contributes to clinical trials by providing vital genomic insights that help in the identification of suitable patient populations and the evaluation of treatment efficacy. Their liquid biopsy tests are often used to support clinical research in oncology, aiding pharmaceutical companies in drug development.
How does Guardant Health ensure data privacy and compliance?
Guardant Health takes data privacy and compliance very seriously, adhering to regulations such as HIPAA (Health Insurance Portability and Accountability Act) and other applicable standards. The company implements stringent security measures to protect patient data and ensure that personal and health information is handled responsibly.
How does Guardant Health support cancer researchers?
Guardant Health supports cancer researchers through partnerships and collaborations that aim to advance clinical research and improve cancer therapies. The company provides access to its genomic data and insights, which can facilitate understanding of tumor genetics and development of new treatments.
Is Guardant Health publicly traded?
Yes, Guardant Health, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol GH. The company went public in October 2018, allowing investors to participate in its growth story.
What are Guardant Health's collaborations with pharmaceutical companies?
Guardant Health has established various collaborations with pharmaceutical companies to enhance drug development and improve patient outcomes. Through these partnerships, the company provides genomic data that can guide the development of targeted therapies and enable better clinical trial designs.
What are the benefits of liquid biopsy over traditional tissue biopsy?
Liquid biopsy offers several benefits over traditional tissue biopsy, including being minimally invasive, providing rapid results, and allowing for real-time monitoring of tumor dynamics. Patients can avoid the discomfort and complications associated with surgical biopsies, while clinicians gain timely insights that can inform treatment decisions.
What are the company's long-term goals?
Guardant Health's long-term goals include expanding its portfolio of liquid biopsy tests to cover a wider range of cancers, enhancing diagnostic capabilities, and improving patient outcomes through precision oncology. The company is focused on driving innovation in cancer care and contributing to improved survival rates.
What are the key markets served by Guardant Health?
Guardant Health primarily serves oncologists, patients, and the broader healthcare community in the United States and internationally. The company's tests are particularly beneficial for individuals diagnosed with various types of cancer, enabling earlier detection and more personalized treatment paths.
What does Guardant Health, Inc. do?
Guardant Health, Inc. is a precision oncology company that focuses on transforming cancer care through the use of non-invasive blood tests. The company aims to improve cancer detection and treatment through advanced genomic insights derived from circulating tumor DNA (ctDNA). Their Liquid Biopsy tests enable clinicians to access vital genomic information in real-time to personalize treatment plans and monitor the effectiveness of therapies.
What is ctDNA and why is it important?
ctDNA, or circulating tumor DNA, refers to small fragments of DNA released from cancer cells into the bloodstream. It is crucial for liquid biopsy tests, as it provides valuable genetic information about the tumor without the need for invasive tissue biopsies, allowing for real-time monitoring of tumor burden and treatment responses.
What is the future outlook for Guardant Health, Inc.?
The future outlook for Guardant Health, Inc. appears promising as the demand for non-invasive cancer diagnostics continues to grow. With ongoing innovations in its testing technologies and a commitment to research and development, the company is well-positioned to advance precision oncology and expand its market presence.
What is the guardant health impact on patient care?
Guardant Health impacts patient care by providing oncologists and healthcare providers with actionable genomic insights that can guide treatment decisions. This personalized approach to cancer care can lead to more effective therapies, improved patient outcomes, and a greater quality of life for cancer patients.
What is the primary product offered by Guardant Health?
Guardant Health's primary product is the Guardant360 test, which is a comprehensive liquid biopsy that analyzes ctDNA from a blood sample to identify genomic alterations in solid tumors. This test is used to provide insights into treatment decisions for patients with advanced cancer.
What is the significance of Guardant's research and development?
Guardant Health places significant emphasis on research and development (R&D) as it is essential for advancing its technology and product offerings. The company's R&D efforts are focused on enhancing the accuracy of its tests, discovering new biomarkers, and developing new testing capabilities that can better serve the oncology community.
When was Guardant Health, Inc. founded?
Guardant Health, Inc. was founded in 2012. Since its inception, the company has been dedicated to revolutionizing cancer diagnosis and management through innovative technologies and precision medicine.
Where is Guardant Health, Inc. headquartered?
Guardant Health, Inc. is headquartered in Redwood City, California. This location places the company in the heart of Silicon Valley, a region known for its innovation and advancements in technology, including healthcare technologies and biotechnology.
Who are Guardant Health's major competitors?
Guardant Health's major competitors include other companies in the liquid biopsy space such as Foundation Medicine, Caris Life Sciences, and Grail, among others. These companies also focus on precision oncology and offer molecular testing services, making it a highly competitive market in the field of cancer diagnostics.
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 40.29
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 4.08B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 101.30M shares outstanding.